NanOlogy™ has transformed systemic chemotherapy into local delivery directly to the site of disease to improve the lives of patients with cancer.

**OVERVIEW**

NanOlogy, LLC is a clinical stage pharmaceutical development company formed by the collaboration of DFB Pharmaceuticals, CritiTech, and US Biotest to advance our patented submicron particle production technology platform for the treatment of cancer and other serious illnesses.

Starting with the world’s most prescribed systemic chemotherapy agents, our technology platform reduces unprocessed paclitaxel and docetaxel API crystals by up to 400 times into patented, stable, naked submicron particles with tremendous surface area and unique geometry.

**NanOlogy has developed** these submicron particles into sterile suspension, topical, and inhalable product forms and has extensive clinical and preclinical programs underway to evaluate these investigational products across multiple indications in cancer and related illnesses.

**STRONG VALUE PROPOSITION**

- Streamlined Path to Regulatory Approval
- Six Phase 2 Clinical Trials Underway
- Clinical Results in 2018
- Preclinical Data in Lung, Prostate, Breast, Ovarian, and Bladder Cancers
- Potential synergy with other therapies
- Extensive Intellectual Property Portfolio including composition patent on the particles
- Indications under evaluation total more than $13 Billion in annual US treatment costs

---

**HIGHLIGHTS**

- **Innovative approach**
  Patented technology transforms paclitaxel and docetaxel into submicron particle NanoPac® and NanoDoce® for direct delivery to disease site.

- **Extensive pipeline**
  Six Phase 2 trials ongoing in ovarian, prostate and pancreatic cancers, cutaneous metastases, pancreatic cysts and actinic keratosis.

- **Partnering opportunities**
  Seeking partners to advance development through pivotal trials, regulatory approval, and to market.
PROMISING PRECLINICAL/CLINICAL DATA

STERILE SUSPENSION FOR INSTILLATION
- Ovarian tumor eradication in preclinical studies
- 5 of 21 salvage patients survived > 400 days in phase 1 ovarian trial
- Clearance from peritoneum > 4 weeks at subtoxic levels
- No drug related adverse events or bowel obstruction in phase 1 ovarian trial

STERILE SUSPENSION FOR DIRECT INJECTION
- Sustained tumor reduction or eradication across multiple tumor types in preclinical studies
- Gradual clearance from injection site at low levels in preclinical studies
- No serious adverse events to date in phase 2 clinical trials

TOPICAL
- Evidence of AK lesion reduction in phase 2 trial
- No local irritation and negligible systemic absorption following topical application over 28 days

NEBULIZED INHALATION
- Preclinical pharmacology study has been completed in NSCLC
- Drug retained in lung tissue > 14 days and no gross or histological abnormalities in lung tissue observed in preclinical PK studies

ACCELERATED DEVELOPMENT PIPELINE
Investigational products in nonclinical or clinical development

<table>
<thead>
<tr>
<th>Product</th>
<th>Delivery</th>
<th>Sponsor</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>NanoPac® for Suspension</td>
<td>Intraperitoneal Instillation</td>
<td>NanOlogy</td>
<td>Ovarian Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intratumoral</td>
<td>NanOlogy</td>
<td>Prostate Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intratumoral</td>
<td>NanOlogy</td>
<td>Pancreatic Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intracystic</td>
<td>NanOlogy</td>
<td>Pancreatic Cyst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NanoPac® for Nebulized Inhalation Nanoparticle Facilitator</td>
<td>Lung Inhalation</td>
<td>NanOlogy</td>
<td>Non Small Cell Lung Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NanoDoce® for Suspension Sterile Nanoparticle Facilitator</td>
<td>Local</td>
<td>NanOlogy</td>
<td>Bladder Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NanoPac® Ointment (SOR007) Nanoparticle Facilitator Ointment</td>
<td>Topical</td>
<td>NanOlogy</td>
<td>Cutaneous Metastases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topical</td>
<td>Soria</td>
<td>Actinic Keratosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

THE NANOLOGY MANAGEMENT TEAM

H. Paul Dorman, Chairman & CEO, DFB Pharmaceuticals
Gere diZerega, MD, CEO, US Biotest
Mark Mitchell, Chief Legal Officer & Managing Director, DFB Pharmaceuticals
Maxwell Lea, Managing Director, DFB Pharmaceuticals

Marc Iacobucci, Managing Director, DFB Pharmaceuticals
Sam Campbell, Chairman, CritiTech
Matthew Mcclure, President, CritiTech
Michael Baltezor, PhD, Chief Scientific Officer, CritiTech

NANOLOGY ADVISORS

Maurie Markman, MD, MS, FACP, FASCO, President, Medicine & Science, Cancer Treatment Centers of America®

© 2018 Nanology, LLC